Symbols / LUNG $1.61 -4.17%
LUNG Chart
About
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 66.41M |
| Enterprise Value | 54.61M | Income | -54.00M | Sales | 90.50M |
| Book/sh | 1.30 | Cash/sh | 1.65 | Dividend Yield | — |
| Payout | 0.00% | Employees | 296 | IPO | — |
| P/E | — | Forward P/E | -1.59 | PEG | — |
| P/S | 0.73 | P/B | 1.24 | P/C | — |
| EV/EBITDA | -1.04 | EV/Sales | 0.60 | Quick Ratio | 4.11 |
| Current Ratio | 5.07 | Debt/Eq | 104.15 | LT Debt/Eq | — |
| EPS (ttm) | -1.33 | EPS next Y | -1.01 | EPS Growth | — |
| Revenue Growth | -4.90% | Earnings | 2026-04-29 | ROA | -22.96% |
| ROE | -77.19% | ROIC | — | Gross Margin | 74.19% |
| Oper. Margin | -43.82% | Profit Margin | -59.67% | Shs Outstand | 41.25M |
| Shs Float | 37.76M | Short Float | 11.72% | Short Ratio | 9.27 |
| Short Interest | — | 52W High | 8.12 | 52W Low | 1.31 |
| Beta | 0.12 | Avg Volume | 517.12K | Volume | 466.85K |
| Target Price | $5.17 | Recom | Buy | Prev Close | $1.68 |
| Price | $1.61 | Change | -4.17% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.17
Mean price target
2. Current target
$1.61
Latest analyst target
3. DCF / Fair value
$-5.47
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.61
Low
$2.50
High
$14.00
Mean
$5.17
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-05 | main | Canaccord Genuity | Buy → Buy | $5 |
| 2026-03-05 | main | D. Boral Capital | Buy → Buy | $14 |
| 2026-02-20 | main | D. Boral Capital | Buy → Buy | $14 |
| 2025-11-13 | main | D. Boral Capital | Buy → Buy | $14 |
| 2025-10-28 | main | Lake Street | Buy → Buy | $4 |
| 2025-10-28 | main | D. Boral Capital | Buy → Buy | $14 |
| 2025-09-08 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-08-01 | main | Wells Fargo | Equal-Weight → Equal-Weight | $3 |
| 2025-07-31 | main | Lake Street | Buy → Buy | $8 |
| 2025-07-31 | main | Stifel | Buy → Buy | $5 |
| 2025-07-31 | down | Piper Sandler | Overweight → Neutral | $3 |
| 2025-07-31 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-05-22 | main | Citigroup | Neutral → Neutral | $4 |
| 2025-05-01 | main | Canaccord Genuity | Buy → Buy | $15 |
| 2025-05-01 | reit | Piper Sandler | Overweight → Overweight | $9 |
| 2025-05-01 | main | D. Boral Capital | Buy → Buy | $17 |
| 2025-03-11 | main | D. Boral Capital | Buy → Buy | $17 |
| 2025-03-10 | init | D. Boral Capital | — → Buy | $17 |
| 2025-02-20 | main | Citigroup | Neutral → Neutral | $8 |
| 2024-12-11 | main | Wells Fargo | Equal-Weight → Equal-Weight | $8 |
- $LUNG stock is up 11% today. Here's what we see in our data. - Quiver Quantitative hu, 05 Mar 2026 19
- Lung cancer sputum test surges 99%, patients avoid risky procedures - Stock Titan Fri, 13 Mar 2026 12
- Immutep stock plunges 80% after lung cancer trial halted - Investing.com Fri, 13 Mar 2026 12
- Is Pulmonx Corporation (LUNG) One of the Best Stocks Under $3 to Invest In? - Yahoo Finance Fri, 31 Oct 2025 07
- bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth - Benzinga Fri, 13 Mar 2026 14
- Gossamer Bio shares plummet as lung disease drug fails late-stage trial - Reuters Mon, 23 Feb 2026 08
- Pulmonx Corporation (LUNG) Releases Q4 2025 Earnings: Revenue Down, Diluted Loss Per Share Widens - Quiver Quantitative ue, 10 Mar 2026 21
- Lung device maker Pulmonx trims losses, guides 2026 sales to $90–92M - Stock Titan Wed, 04 Mar 2026 08
- Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance Wed, 04 Mar 2026 08
- Pulmonx CEO French sells $13.8k in LUNG stock - Investing.com Wed, 03 Dec 2025 08
- Soleus group holds 2.67M Pulmonx shares (LUNG) — 6.5% stake disclosed - Stock Titan Mon, 09 Mar 2026 21
- After Plunging 37.5% in 4 Weeks, Here's Why the Trend Might Reverse for Pulmonx (LUNG) - Yahoo Finance ue, 05 Aug 2025 07
- $LUNG stock is up 14% today. Here's what we see in our data. - Quiver Quantitative ue, 09 Dec 2025 08
- Pulmonx (Nasdaq: LUNG) reappoints Glen French as CEO; preliminary Q3 revenue ~$21.5M - Stock Titan Mon, 27 Oct 2025 07
- What New Catalysts Are Shifting the Pulmonx Story for Investors - Yahoo Finance Wed, 10 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 7732 | 11057 | — | Sale at price 1.43 per share. | ROSE GEOFFREY BERAN | Officer | — | 2026-03-02 00:00:00 | D |
| 1 | 10483 | 14991 | — | Sale at price 1.43 per share. | RADHAKRISHNAN SRIKANTH | Chief Technology Officer | — | 2026-03-02 00:00:00 | D |
| 2 | 67813 | 96973 | — | Sale at price 1.43 per share. | FRENCH GLENDON E III | Chief Executive Officer | — | 2026-03-02 00:00:00 | D |
| 3 | 12237 | 17499 | — | Sale at price 1.43 per share. | LEHMAN DAVID AARON | General Counsel | — | 2026-03-02 00:00:00 | D |
| 4 | 100000 | — | — | Stock Award(Grant) at price 0.00 per share. | ROSE GEOFFREY BERAN | Officer | — | 2026-03-02 00:00:00 | D |
| 5 | 175000 | — | — | Stock Award(Grant) at price 0.00 per share. | RADHAKRISHNAN SRIKANTH | Chief Technology Officer | — | 2026-03-02 00:00:00 | D |
| 6 | 150000 | — | — | Stock Award(Grant) at price 0.00 per share. | LEHMAN DAVID AARON | General Counsel | — | 2026-03-02 00:00:00 | D |
| 7 | 23321 | 46409 | — | Sale at price 1.99 per share. | FLORIN DANIEL P | Director | — | 2025-12-08 00:00:00 | D |
| 8 | 6322 | 9926 | — | Sale at price 1.57 per share. | ROSE GEOFFREY BERAN | Officer | — | 2025-12-01 00:00:00 | D |
| 9 | 8805 | 13824 | — | Sale at price 1.57 per share. | FRENCH GLENDON E III | Chief Executive Officer | — | 2025-12-01 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -50.89M | -55.49M | -55.99M | -46.62M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -56.39M | -60.84M | -58.92M | -48.66M |
| ReconciledDepreciation | 1.49M | 1.55M | 1.51M | 867.00K |
| ReconciledCostOfRevenue | 21.79M | 17.92M | 13.80M | 12.79M |
| EBITDA | -50.89M | -55.49M | -55.99M | -46.62M |
| EBIT | -52.39M | -57.04M | -57.50M | -47.49M |
| NetInterestIncome | 1.55M | 2.34M | 463.00K | -429.00K |
| InterestExpense | 3.51M | 3.23M | 1.07M | 829.00K |
| InterestIncome | 5.06M | 5.57M | 1.53M | 400.00K |
| NormalizedIncome | -56.39M | -60.84M | -58.92M | -48.66M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -56.39M | -60.84M | -58.92M | -48.66M |
| TotalExpenses | 141.49M | 130.61M | 112.30M | 95.72M |
| TotalOperatingIncomeAsReported | -57.70M | -61.94M | -58.64M | -47.30M |
| DilutedAverageShares | 40.69M | 39.11M | 37.97M | 37.10M |
| BasicAverageShares | 40.69M | 39.11M | 37.97M | 37.10M |
| DilutedEPS | -1.33 | -1.44 | -1.60 | -1.59 |
| BasicEPS | -1.33 | -1.44 | -1.60 | -1.59 |
| DilutedNIAvailtoComStockholders | -56.39M | -60.84M | -58.92M | -48.66M |
| NetIncomeCommonStockholders | -56.39M | -60.84M | -58.92M | -48.66M |
| NetIncome | -56.39M | -60.84M | -58.92M | -48.66M |
| NetIncomeIncludingNoncontrollingInterests | -56.39M | -60.84M | -58.92M | -48.66M |
| NetIncomeContinuousOperations | -56.39M | -60.84M | -58.92M | -48.66M |
| TaxProvision | 500.00K | 571.00K | 353.00K | 343.00K |
| PretaxIncome | -55.89M | -60.27M | -58.57M | -48.32M |
| OtherIncomeExpense | 256.00K | -673.00K | -396.00K | -585.00K |
| OtherNonOperatingIncomeExpenses | 256.00K | -673.00K | -396.00K | -585.00K |
| NetNonOperatingInterestIncomeExpense | 1.55M | 2.34M | 463.00K | -429.00K |
| InterestExpenseNonOperating | 3.51M | 3.23M | 1.07M | 829.00K |
| InterestIncomeNonOperating | 5.06M | 5.57M | 1.53M | 400.00K |
| OperatingIncome | -57.70M | -61.94M | -58.64M | -47.30M |
| OperatingExpense | 119.70M | 112.69M | 98.50M | 82.93M |
| ResearchAndDevelopment | 17.57M | 18.08M | 15.40M | 13.06M |
| SellingGeneralAndAdministration | 102.14M | 94.61M | 83.11M | 69.87M |
| GrossProfit | 62.00M | 50.75M | 39.87M | 35.63M |
| CostOfRevenue | 21.79M | 17.92M | 13.80M | 12.79M |
| TotalRevenue | 83.79M | 68.67M | 53.66M | 48.42M |
| OperatingRevenue | 83.79M | 68.67M | 53.66M | 48.42M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 39.79M | 38.52M | 37.56M | 36.93M |
| ShareIssued | 39.79M | 38.52M | 37.56M | 36.93M |
| TotalDebt | 56.47M | 41.42M | 24.40M | 26.46M |
| TangibleBookValue | 83.48M | 115.95M | 151.52M | 190.63M |
| InvestedCapital | 122.99M | 155.56M | 171.33M | 210.65M |
| WorkingCapital | 111.81M | 127.27M | 150.46M | 190.45M |
| NetTangibleAssets | 83.48M | 115.95M | 151.52M | 190.63M |
| CapitalLeaseObligations | 19.29M | 4.18M | 7.08M | 9.04M |
| CommonStockEquity | 85.81M | 118.31M | 154.01M | 193.24M |
| TotalCapitalization | 119.81M | 153.40M | 171.24M | 210.56M |
| TotalEquityGrossMinorityInterest | 85.81M | 118.31M | 154.01M | 193.24M |
| StockholdersEquity | 85.81M | 118.31M | 154.01M | 193.24M |
| GainsLossesNotAffectingRetainedEarnings | 2.11M | 2.64M | 1.57M | 1.71M |
| OtherEquityAdjustments | 2.11M | 2.64M | 1.57M | 1.71M |
| RetainedEarnings | -467.56M | -411.16M | -350.32M | -291.39M |
| AdditionalPaidInCapital | 551.21M | 526.80M | 502.71M | 482.88M |
| CapitalStock | 40.00K | 39.00K | 38.00K | 37.00K |
| CommonStock | 40.00K | 39.00K | 38.00K | 37.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 77.04M | 59.47M | 39.67M | 41.93M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 52.60M | 36.31M | 21.18M | 24.38M |
| OtherNonCurrentLiabilities | 179.00K | |||
| NonCurrentDeferredLiabilities | 87.00K | 114.00K | 94.00K | 37.00K |
| NonCurrentDeferredTaxesLiabilities | 87.00K | 114.00K | 94.00K | 37.00K |
| LongTermDebtAndCapitalLeaseObligation | 52.52M | 36.20M | 21.08M | 24.17M |
| LongTermCapitalLeaseObligation | 18.52M | 1.11M | 3.85M | 6.84M |
| LongTermDebt | 34.00M | 35.09M | 17.23M | 17.32M |
| CurrentLiabilities | 24.44M | 23.16M | 18.49M | 17.55M |
| CurrentDeferredLiabilities | 135.00K | 104.00K | 120.00K | 163.00K |
| CurrentDeferredRevenue | 135.00K | 104.00K | 120.00K | 163.00K |
| CurrentDebtAndCapitalLeaseObligation | 3.95M | 5.23M | 3.32M | 2.29M |
| CurrentCapitalLeaseObligation | 778.00K | 3.07M | 3.23M | 2.20M |
| CurrentDebt | 3.18M | 2.15M | 90.00K | 91.00K |
| OtherCurrentBorrowings | 3.18M | 2.15M | 90.00K | 91.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 6.89M | 7.88M | 4.97M | 4.74M |
| PayablesAndAccruedExpenses | 13.45M | 9.95M | 10.08M | 10.35M |
| CurrentAccruedExpenses | 8.75M | 7.60M | 7.68M | 7.89M |
| Payables | 4.70M | 2.35M | 2.40M | 2.46M |
| TotalTaxPayable | 876.00K | 856.00K | 646.00K | 877.00K |
| IncomeTaxPayable | 49.00K | 93.00K | 19.00K | 147.00K |
| AccountsPayable | 3.83M | 1.50M | 1.76M | 1.58M |
| TotalAssets | 162.85M | 177.78M | 193.68M | 235.17M |
| TotalNonCurrentAssets | 26.60M | 27.36M | 24.72M | 27.17M |
| OtherNonCurrentAssets | 2.82M | 3.17M | 5.81M | 731.00K |
| InvestmentsAndAdvances | 0.00 | 14.39M | 5.92M | 10.94M |
| InvestmentinFinancialAssets | 0.00 | 14.39M | 5.92M | 10.94M |
| AvailableForSaleSecurities | 14.39M | 5.92M | 10.94M | |
| GoodwillAndOtherIntangibleAssets | 2.33M | 2.36M | 2.49M | 2.61M |
| OtherIntangibleAssets | 31.00K | 154.00K | 277.00K | |
| Goodwill | 2.33M | 2.33M | 2.33M | 2.33M |
| NetPPE | 21.45M | 7.43M | 10.50M | 12.89M |
| AccumulatedDepreciation | -5.72M | -4.86M | -3.56M | -2.24M |
| GrossPPE | 27.18M | 12.29M | 14.06M | 15.13M |
| Leases | 2.32M | 2.28M | 2.28M | 2.28M |
| ConstructionInProgress | 206.00K | 2.20M | 1.82M | 1.33M |
| OtherProperties | 18.55M | 3.41M | 5.81M | 8.07M |
| MachineryFurnitureEquipment | 6.11M | 4.41M | 4.15M | 3.45M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 136.25M | 150.42M | 168.95M | 208.00M |
| OtherCurrentAssets | 1.13M | 504.00K | 290.00K | 347.00K |
| RestrictedCash | 257.00K | 237.00K | 231.00K | 231.00K |
| PrepaidAssets | 2.67M | 2.82M | 3.45M | 4.17M |
| Inventory | 16.91M | 16.74M | 14.56M | 16.29M |
| FinishedGoods | 12.03M | |||
| WorkInProcess | 518.00K | |||
| RawMaterials | 3.74M | |||
| Receivables | 13.79M | 13.02M | 9.28M | 6.92M |
| TaxesReceivable | 671.00K | 915.00K | 602.00K | 362.00K |
| AccountsReceivable | 13.12M | 12.11M | 8.68M | 6.56M |
| AllowanceForDoubtfulAccountsReceivable | -100.00K | 0.00 | -100.00K | -100.00K |
| GrossAccountsReceivable | 13.22M | 12.11M | 8.78M | 6.66M |
| CashCashEquivalentsAndShortTermInvestments | 101.48M | 117.10M | 141.14M | 180.04M |
| OtherShortTermInvestments | 30.58M | 33.55M | 39.40M | 31.56M |
| CashAndCashEquivalents | 70.91M | 83.55M | 101.74M | 148.48M |
| CashEquivalents | 6.62M | 25.13M | 4.65M | 7.24M |
| CashFinancial | 64.29M | 58.42M | 97.09M | 141.24M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -32.98M | -38.42M | -46.40M | -45.06M |
| RepaymentOfDebt | -95.00K | -94.00K | -87.00K | 0.00 |
| IssuanceOfDebt | 0.00 | 20.00M | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 0.00 | |||
| CapitalExpenditure | -1.45M | -807.00K | -1.32M | -3.67M |
| InterestPaidSupplementalData | 3.48M | 2.98M | 847.00K | 722.00K |
| IncomeTaxPaidSupplementalData | 556.00K | 471.00K | 398.00K | 322.00K |
| EndCashPosition | 71.16M | 83.78M | 101.97M | 148.71M |
| BeginningCashPosition | 83.78M | 101.97M | 148.71M | 231.79M |
| EffectOfExchangeRateChanges | 76.00K | 34.00K | 145.00K | 106.00K |
| ChangesInCash | -12.70M | -18.22M | -46.89M | -83.19M |
| FinancingCashFlow | 1.36M | 21.40M | 2.42M | 4.46M |
| CashFlowFromContinuingFinancingActivities | 1.36M | 21.40M | 2.42M | 4.46M |
| NetOtherFinancingCharges | -53.00K | -41.00K | ||
| ProceedsFromStockOptionExercised | 1.46M | 1.49M | 2.56M | 4.50M |
| NetCommonStockIssuance | 0.00 | |||
| CommonStockIssuance | 0.00 | |||
| NetIssuancePaymentsOfDebt | -95.00K | 19.91M | -87.00K | 0.00 |
| NetLongTermDebtIssuance | -95.00K | 19.91M | -87.00K | 0.00 |
| LongTermDebtPayments | -95.00K | -94.00K | -87.00K | 0.00 |
| LongTermDebtIssuance | 0.00 | 20.00M | 0.00 | 0.00 |
| InvestingCashFlow | 17.48M | -2.01M | -4.22M | -46.26M |
| CashFlowFromContinuingInvestingActivities | 17.48M | -2.01M | -4.22M | -46.26M |
| NetInvestmentPurchaseAndSale | 18.92M | -1.20M | -2.91M | -42.58M |
| SaleOfInvestment | 46.84M | 45.00M | 44.28M | 10.00M |
| PurchaseOfInvestment | -27.91M | -46.20M | -47.19M | -52.58M |
| NetPPEPurchaseAndSale | -1.45M | -807.00K | -1.32M | -3.67M |
| PurchaseOfPPE | -1.45M | -807.00K | -1.32M | -3.67M |
| OperatingCashFlow | -31.54M | -37.61M | -45.08M | -41.39M |
| CashFlowFromContinuingOperatingActivities | -31.54M | -37.61M | -45.08M | -41.39M |
| ChangeInWorkingCapital | -1.70M | -2.56M | -7.01M | -7.85M |
| ChangeInOtherWorkingCapital | -16.00K | 4.00K | 8.00K | 88.00K |
| ChangeInOtherCurrentLiabilities | -1.87M | -3.18M | -2.20M | -2.52M |
| ChangeInOtherCurrentAssets | -546.00K | -36.00K | -49.00K | -221.00K |
| ChangeInPayablesAndAccruedExpense | 2.70M | 2.90M | 272.00K | 4.91M |
| ChangeInAccruedExpense | 462.00K | 3.18M | 149.00K | 4.80M |
| ChangeInPayable | 2.24M | -277.00K | 123.00K | 108.00K |
| ChangeInAccountPayable | 2.28M | -345.00K | 247.00K | 87.00K |
| ChangeInTaxPayable | -38.00K | 68.00K | -124.00K | 21.00K |
| ChangeInIncomeTaxPayable | -38.00K | 68.00K | -124.00K | 21.00K |
| ChangeInPrepaidAssets | -436.00K | -57.00K | 780.00K | -1.21M |
| ChangeInInventory | -229.00K | 918.00K | -3.64M | -6.46M |
| ChangeInReceivables | -1.31M | -3.10M | -2.19M | -2.43M |
| ChangesInAccountReceivables | -1.31M | -3.10M | -2.19M | -2.43M |
| OtherNonCashItems | 1.90M | 2.73M | 2.55M | 2.47M |
| StockBasedCompensation | 22.95M | 22.10M | 16.45M | 10.53M |
| ProvisionandWriteOffofAssets | 40.00K | -59.00K | 54.00K | 4.00K |
| AssetImpairmentCharge | 1.79M | 507.00K | 485.00K | 1.19M |
| AmortizationOfSecurities | -1.62M | -1.02M | -204.00K | 59.00K |
| DepreciationAmortizationDepletion | 1.49M | 1.55M | 1.51M | 867.00K |
| DepreciationAndAmortization | 1.49M | 1.55M | 1.51M | 867.00K |
| OperatingGainsLosses | -15.00K | 7.00K | ||
| GainLossOnSaleOfPPE | 0.00 | -15.00K | 7.00K | |
| NetIncomeFromContinuingOperations | -56.39M | -60.84M | -58.92M | -48.66M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for LUNG
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|